Combination drug therapy for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs for cervical cancer that has returned or spread after initial treatment. The drugs target cancer cells with a specific marker called HER2 and may help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- You have cervical cancer that has come back or spread after first-line treatment.
- Your tumor shows a certain level of HER2 (a protein) on its surface.
- You have at least one measurable tumor.
- You are generally healthy enough to receive treatment (able to care for yourself, with adequate organ function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs together for people with cervical cancer that has returned or spread. The goal is to see if the combination can shrink tumors or slow the disease better than current options.
This trial tests a combination of three drugs—camrelizumab (an immunotherapy that helps your immune system fight cancer), famitinib (a targeted therapy that blocks blood vessel growth to tumors), and standard chemotherapy—for cervical cancer that has come back or spread and cannot be removed with surgery or radiation. The goal is to see if this combination is safe and effective.
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
This trial tests a new combination of an immunotherapy drug (QL1706) and a vaccine for people with cervical cancer that has not improved, came back, or spread. It aims to see if this combination can help control the cancer better than current options.
This trial tests a combination of new immunotherapy drugs (LB1410 and maybe LB4330) with lenvatinib (a targeted therapy) in patients with advanced cervical cancer that came back or spread. The goal is to see if this combo shrinks tumors or slows the cancer better than standard options.
This trial tests a combination of two drugs (nimotuzumab and tislelizumab) alongside radiation therapy for people whose cervical cancer has returned or spread to a few other places. The goal is to see if this approach can help control the cancer better and improve survival.
Hear when a new Recurrent Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.